SpyGlass Pharma has acquired Advanced Vision Science (AVS) from Santen Pharmaceutical for $13 million in cash. The deal secures critical, scalable manufacturing capacity for the company's intraocular lenses, directly supporting its ongoing Phase 3 registrational trials for the BIM-IOL System.
SpyGlass Pharma has acquired Advanced Vision Science (AVS) for $13 million in cash to internalize its supply chain for intraocular lenses. By securing AVS, which currently supplies the IOLs used in SpyGlass's two ongoing Phase 3 registrational trials for the BIM-IOL System, the company mitigates supply chain risks and gains the scalable manufacturing capacity necessary for future commercialization.
- ▲ Acquisition of AVS secures scalable commercial IOL manufacturing capacity
- ▲ Direct control over the supply chain for the BIM-IOL System currently in Phase 3 trials
- ▼ Integration risks associated with absorbing AVS operations
- ▼ Potential for Phase 3 trial failure of the BIM-IOL System
▼ Show FAQ (2) ▲ Hide FAQ
What was the cost of the acquisition?
SpyGlass Pharma acquired AVS for approximately $13 million in cash.
Why is AVS important to SpyGlass Pharma?
AVS is the current supplier of the IOLs used in SpyGlass Pharma's two Phase 3 registrational trials for the BIM-IOL System.